Picture of Eric Price

Eric Price B.Sc., Ph.D.

Assistant Professor

Faculty Member in Chemistry

Thorvaldson 347

Research Area(s)

  • Synthesis and characterization of new radiopharmaceuticals for PET/SPECT/fluorescent molecular imaging
  • New chelators for improved radiolabeling and stability with radiometals such as zirconium-89
  • Modified peptides for imaging and treating cancer and bacterial infections using radiometals


1) Price, Eric W., Orvig, C.  The Chemistry of Inorganic Nuclides (86Y, 68Ga, 64Cu, 89Zr, 124I).  In The Chemistry of Molecular Imaging.  N. J. Long, W.-T. Wong, Eds.  Wiley, 2014, 105-135.
2) Price, Eric W., Zeglis, B. M., Cawthray, J. F., Lewis, J. S., Adam, M. J., Orvig, C. What a Difference a Carbon Makes: H4octapa vs. H4C3octapa, Ligands for In-111 and Lu-177 Radiochemistry. Inorg. Chem. 2014, 53 (19), 10412-10431.
3) Price, Eric W., Cawthray, J. F, Adam, M. J., Orvig, C. Modular Syntheses of H4octapa and H2dedpa, and Yttrium Coordination Chemistry Relevant to 86/90Y Radiopharmaceuticals. Dalton Trans. 2014, 43 (19), 7176-7190.
4) Price, Eric W., Ferreira, C. L., Adam, M. J., Orvig, C. High Denticity Ligands Based on Picolinic Acid for In-111 Radiochemistry. Can. J. Chem. 2014, 92 (8), 695-705 (invited Barry Lever special issue).
5) Price, Eric W., Zeglis, B. M., Lewis, J. S., Adam, M. Orvig, C. H6phospa-Trastuzumab: Bifunctional Methylenephosphonate-based Chelator with 89Zr, 111In and 177Lu. Dalton Trans. 2014, 43 (1), 119-131.
6) Price, Eric W., Orvig, C. Matching Chelators to Radiometals for Radiopharmaceuticals. Chem. Soc. Rev. 2014, 42 (1), 260-290.
7) Price, Eric W.; Zeglis, B. M.; Cawthray, J. F.; Ramogida, C. F.; Ramos, N.; Lewis, J. S.; Adam, M. J.; Orvig, C., H4octapa-Trastuzumab: The Application of a Versatile Acyclic Chelate System for 111In and 177Lu Imaging and Therapy. J. Am. Chem. Soc. 2013, 135 (34), 12707–12721.
8) Boros, E.; Ferreira, C. L.; Yapp, D. T. T.; Gill, R. K.; Price, Eric W.; Adam, M. J.; Orvig, C., RGD conjugates of the H2dedpa scaffold: synthesis, labeling and imaging with 68Ga. Nucl. Med. Biol. 2012, 39 (6), 785-794.
9) Price, Eric W.; Cawthray, J. F.; Bailey, G. A.; Ferreira, C. L.; Boros, E.; Adam, M. J.; Orvig, C., H4octapa: An Acyclic Chelator for 111In Radiopharmaceuticals. J. Am. Chem. Soc. 2012, 134 (20), 8670-8683.
10) Bailey, G. A.*; Price, Eric W.*; Zeglis, B. M.; Ferreira, C. L.; Boros, E.; Lacasse, M. J.; Patrick, B. O.; Lewis, J. S.; Adam, M. J.; Orvig, C., H2azapa: a Versatile Acyclic Multifunctional Chelator for 67Ga, 64Cu, 111In, and 177Lu. Inorg. Chem. 2012, 51 (22), 12575-12589. *These authors contributed equally to this work.
11) Price, Eric W.; Harirchian-Saei, S.; Moffitt, M. G., Strands, Networks, and Continents from Polystyrene Dewetting at the Air-Water Interface: Implications for Amphiphilic Block Copolymer Self-Assembly. Langmuir 2011, 27 (4), 1364-1372. Invited manuscript for ACS Langmuir special issue: Supramolecular Chemistry at Interfaces.
12) Boros, E.; Ferreira, C. L.; Cawthray, J. F.; Price, Eric W.; Patrick, B. O.; Wester, D. W.; Adam, M. J.; Orvig, C., Acyclic Chelate with Ideal Properties for 68Ga PET Imaging Agent Elaboration. J. Am. Chem. Soc. 2010, 132 (44), 15726-15733.
13) Price, Eric W.; Guo, Y.; Wang, C. W.; Moffitt, M. G., Block Copolymer Strands with Internal Microphase Separation Structure via Self-Assembly at the Air-Water Interface. Langmuir 2009, 25 (11), 6398-6406. (NSERC USRA funded undergraduate research term).
1) Adam, Michael; Boros, Eszter; Ferreira, Cara, L.; Orvig, C.; Price, Eric W.  Bifunctional Chelating Agents. EP Patent 2,536,691, USA #20110313130 A1, published December 22, 2011, International WO2011100829 A1, published August 25, 2011.


Bacteria Cancer Inorganic chemistry Molecular imaging Organic chemistry Positron emission tomography (PET) Radiochemistry Radiometals Radiopharmaceuticals

Two fields of health research that are critical both in Canada and worldwide are cancer and antibiotic-resistant bacterial infections. Both of these health conditions can benefit greatly from new and innovative radiopharmaceutical agents (radioactive medicines) for early detection, staging, and selective treatment. Broadly, the research of Dr. Price's lab involves the synthesis and fundamental chemistry and characterization of new radiometal-based radiopharmaceuticals (e.g., radioactive metals combined with peptides, antibodies, and nanoparticles) for both imaging and therapy of many types of cancer and bacterial infections. These new agents have the potential for clinical translation, which could provide a real impact on patient care and quality of life. The cancer-targeted radiopharmaceuticals that Dr. Price studies are selective and sensitive, and utilize radioactive metal isotopes such as indium-111, gallium-68, copper-64, scandium-44, zirconium-89, yttrium-86/90, and lutetium-177. As imaging agents they provide exquisitely accurate and sensitive early detection of cancer, and as therapeutics they have fewer side effects than the highly toxic and non-selective standard chemotherapy drugs still used today. 

Education & Training

BSc Honours, Co-op (2009)
The University of Victoria

PhD (2014)
The University of British Columbia
Supervisor: Dr. Chris Orvig